Ranbaxy's Court Win On Lipitor Generics Leaves Compliance Issues Unanswered
This article was originally published in PharmAsia News
Executive Summary
India's Ranbaxy Laboratories may have been freed to launch a U.S. generic of the world's best-selling drug if it gets U.S. FDA approval, but a court's action allowing it to do so failed to settle several issues roiling within the pharmaceutical industry